Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Last Price: 47.57 - Change: 1.37 - Change %: 2.9654
Industry: Health Information ServicesFollow @stockchartsai on Twitter
In the past 30 trading days, TXG has been trading in a range between $43.42 and $34.32 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
TXG is trading between resistance at $51.36 about 8% to the upside and support at $41.85 -12% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $54.70, about a 15% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
10X Genomics Inc (TXG) entered a Green zone 16 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 4.000, which is a Buy. The current analyst target price is $60.33, which gives it a potential upside of 26.82 % from the recent price of 47.57. The stock is trading 33.63% (potential upside) below its 52 week high of $63.57 and 52.08 % (potential downside) above its 52 week low of $31.28 - based on the recent price.
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
|10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.
Thu, 07 Dec 2023 09:00:00 -0500
|NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics
Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.
Mon, 20 Nov 2023 11:42:27 -0500
|10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG).
Fri, 17 Nov 2023 17:22:00 -0500
|OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.
Mon, 06 Nov 2023 16:05:00 -0500
|10x Genomics: Unveiling The Investment Potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap.
Source: Seeking Alpha
Sat, 04 Nov 2023 01:02:01 -0400
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.